Login to Your Account



Genmab, J&J in $175M Per Product DuoBody Deal

By Cormac Sheridan
Staff Writer

Wednesday, August 8, 2012

Genmab A/S entered its second DuoBody deal with a large pharmaceutical firm inside two months. The Copenhagen, Denmark-based antibody developer entered a broad collaboration with the Johnson & Johnson subsidiary Janssen Biotech Inc. to develop bispecific antibodies against Janssen-supplied targets. It is banking $3.5 million up front and could receive up to $175 million more in milestone and license payments for each successfully developed product.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription